Kooperativer Bibliotheksverbund

In: European Journal of Haematology, Wiley, Vol. 106, No. 1 ( 2021-01), p. 49-57

Abstract: Primary pulmonary lymphoma (PPL) is a rare disease with not well‐defined optimal treatment. Outcomes and follow‐up are variable in published data. Objectives To define the outcome and optimal treatment strategies in PPL. Methods We reviewed the medical records of 49 patients with PPL treated in three Italian Hematological Institutions between 2002 and 2018. Results Thirty‐eight (77.5%) cases were indolent PPL, and 11 (22.5%) cases were aggressive PPL. The majority of patients were asymptomatic at diagnosis, early stages (stages IE‐IIE), normal serum LDH, no bone marrow involvement, and low or low‐intermediate risks of IPI. Local therapy ± immunotherapy or immuno‐chemotherapy was possible in 18/49 (37%) patients. Twenty‐eight (57%) patients were treated with immuno‐chemotherapy after biopsy. Waiting and watching were reported in 3 (6%) patients. Overall, the CR and ORR were 83.7% and 95.9%. With a median follow‐up of 62.5 months (range 0.8‐199 months), the estimated 5‐ and 10‐year OS rates were 85% and 72.3% for all patients, 89.2% and 80.3% for indolent PPL, and 70.7% and 47.1% for aggressive PPL. Aggressive PPL tended to have a high risk of progression in the first months ( P  = .056). No advantages were found for indolent PPL who received immuno‐chemotherapy or more conservative approaches. Conclusion Our studies confirm the epidemiological and favorable survival of patients with PPL, suggesting a very conservative approach, particularly in indolent subtypes.

Type of Medium: Online Resource

ISSN: 0902-4441 , 1600-0609

URL: Issue

URL: Article

DOI: 10.1111/ejh.v106.1

DOI: 10.1111/ejh.13507

Language: English

Publisher: Wiley

Publication Date: 2021

detail.hit.zdb_id: 2027114-1

In: Hematological Oncology, Wiley, Vol. 35, No. 1 ( 2017-03), p. 69-78

Abstract: In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. ‘Early FDG‐PET’ and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG‐PET and TAM; the secondary endpoint was to test if early FDG‐PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG‐PET after two cycles and after the completion of therapy. TAM in diagnostic specimens was determined by immunohistochemistry with a monoclonal antibody (anti‐CD68 KP1). Overall, early FDG‐PET was negative in 163 patients (81.5%) and positive in 37 patients (18.5%), showing a significant correlation with the achievement of CR ( p   〈  0.0001). After a median follow‐up of 40 months, progression free survival (PFS) was significantly better for PET negative patients ( p   〈  0.0001). CD68 expression was low, intermediate or high in 26 (13%), 100 (50%) and 74 (37%) cases, without difference in the distribution between responders and non‐responders. PFS analysis showed no significant difference in any score group. TAM score did not show any correlation with early FDG‐PET result. This study confirms that early FDG‐PET has a high prognostic power, while TAM score does not seem to influence the outcome; in contrast to our original hypothesis, it does not correlate with FDG‐PET assessment. Copyright © 2015 John Wiley & Sons, Ltd.

Type of Medium: Online Resource

ISSN: 0278-0232 , 1099-1069

URL: Issue

URL: Article

DOI: 10.1002/hon.v35.1

DOI: 10.1002/hon.2249

Language: English

Publisher: Wiley

Publication Date: 2017

detail.hit.zdb_id: 2001443-0

In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 11 ( 2021-04-10), p. 1214-1222

Abstract: To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into a prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted the prospective Elderly Project study on patients with DLBCL older than 64 years who underwent our Fondazione Italiana Linfomi original geriatric assessment (oGA) (age, Cumulative Illness Rating Scale for Geriatrics, activities of daily living, and instrumental activities of daily living) before treatment. Treatment choice was left to the physician's discretion. The primary end point was overall survival (OS) (ClinicalTrials.gov identifier: NCT02364050 ). RESULTS We analyzed 1,163 patients (median age 76 years), with a 3-year OS of 65% (95% CI, 62 to 68). Because at multivariate analysis on oGA, age 〉 80 years retained an independent correlation with OS, we also developed a new, simplified version of the GA (sGA) that classifies patients as fit (55%), unfit (28%), and frail (18%) with significantly different 3-year OS of 75%, 58%, and 43%, respectively. The sGA groups, International Prognostic Index, and hemoglobin levels were independent predictors of OS and were used to build the Elderly Prognostic Index (EPI). Three risk groups were identified: low (23%), intermediate (48%), and high (29%), with an estimated 3-year OS of 87% (95% CI, 81 to 91), 69% (95% CI, 63 to 73), and 42% (95% CI, 36 to 49), respectively. The EPI was validated using an independent external series of 328 cases. CONCLUSION The Elderly Project validates sGA as an objective tool to assess fitness status and defines the new EPI to predict OS of older patients with DLBCL.

Type of Medium: Online Resource

ISSN: 0732-183X , 1527-7755

URL: Article

DOI: 10.1200/JCO.20.02465

Language: English

Publisher: American Society of Clinical Oncology (ASCO)

Publication Date: 2021

detail.hit.zdb_id: 2005181-5

In: Leukemia & Lymphoma, Informa UK Limited, Vol. 59, No. 6 ( 2018-06-03), p. 1420-1426

Type of Medium: Online Resource

ISSN: 1042-8194 , 1029-2403

URL: Article

DOI: 10.1080/10428194.2017.1387909

Language: English

Publisher: Informa UK Limited

Publication Date: 2018

detail.hit.zdb_id: 2030637-4

In: International Journal of Psychophysiology, Elsevier BV, Vol. 108 ( 2016-10), p. 88-

Type of Medium: Online Resource

ISSN: 0167-8760

URL: Article

DOI: 10.1016/j.ijpsycho.2016.07.276

Language: English

Publisher: Elsevier BV

Publication Date: 2016

detail.hit.zdb_id: 1500484-3

SSG: 5,2

In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 5451-5451

Abstract: Bendamustine was introduced in Italy from 2008 and it was used as salvage therapy in patients pretreated, particularly in indolent lymphomas. Before approval as first-line treatment by the National Health System, starting from 2011 and thanks to our regional regulation, was possible to use Bendamustine in first line therapy as ‘off-label’ drug. The aim of this study was to collect all consecutive patients treated in first line with Bendamustine in 7 Tuscany centers. From June 2011 to December 2012, 72 patients were prospectively included in the study. Diagnosis was: Lymphocytic lymphoma in 25 patients (34%), Follicular lymphoma in 18 (25%), Diffuse large B cell lymphoma in 11 (15%), Mantle cell lymphoma in 10 (14%), Lymphoplasmocytic lymphoma in 5 (7%) and MALT in 3 (5%). Thirty-nine patients were treated with Bendamustine 90 mg/m2 for two days, 28 with 70 mg/m2 and 5 with 120 mg/m2. The analyzed population must be considered negatively selected as such was not proposed the standard therapy. Moreover the data coming from literature and the experience in pre-treated patients increased the interest of clinicians for this drug. In 14 patients Bendamustine was used alone, in 56 in combination with Rituximab or other drug. The overall median age was 69 years (range 45-89), in DLBCL was 81 years and 78 years in MCL. Considering the advanced age of this population we applied the geriatric score assessment and 25% of patients were unfit or frail. The median number of cycles performed was 4 (range 2 - 6). All patients but 2 were evaluable for response, 35 obtained a complete remission, 27 a partial remission considering the intention to treat the overall response rate was 86%, stable disease in 2 patients, progressive disease in 6 patients and not evaluable in 2 patients. According to histotype to note that all but two indolent lymphoma obtained a response; in aggressive lymphomas 4/11 DLBCL and 5/9 MCL reached a complete remission but 4 DLBCL and 2 MCL experienced rapid progression of the disease. Treatment was well tolerated, we observed: grade 3-4 neutropenia in 18 patients, no grade 3-4 anemia or thrombocytopenia. According to extrahematological toxicity was reported only grade 3-4 infection in 3 patients no other grade 3-4 toxicities were reported. Skin rush grade 1 was reported in in 5 patients. No toxic deaths were observed. After a median follow-up of 18 months the overall survival was 83%; 10 patients died all due to progressive disease. Progression free survival, after a median observation period of 12 months, was 60%; sixty-two patients are alive, 31 in continuous complete remission, 3 relapsed and 28 with disease under control. In conclusion in this ‘real life’ negatively selected population, the use of Bendamustine showed a very high response rate particularly in indolent lymphomas, promising results, also, are observed in aggressive lymphoma suggesting that this drug can be used with interesting result in elderly patients who can not receive the standard therapy. Disclosures No relevant conflicts of interest to declare.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V124.21.5451.5451

Language: English

Publisher: American Society of Hematology

Publication Date: 2014

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 3685-3685

Abstract: Abstract 3685 Background: Ocular adnexal lymphomas (OALs) represents 8% of primary extranodal lymphomas, 80% of OALs constitutes extranodal marginal zone lymphomas (EMZL). In the last years the incidence of OLAs has increased more rapidly than Non Hodgkin Lymphoma at other extranodal site. Radiotherapy is associated to high rates of local disease control, but also to the risk of relapse and immediate and delayed complications, such as xerophtalmy, corneal ulcerations, cataract and retinal damage. Surgery is a feasible option, but not always satisfactory in terms of disease control. Single-agent chemotherapy with alkylating agents is used for the treatment of low-grade lymphomas, including OALs. Rituximab, a chimeric anti-CD20 monoclonal antibody, is effective in EMZL and in OALs. Aims: We investigated the efficacy and the safety of a combination of chlorambucil and rituximab as first line treatment in patients with OALs. Methods: Patients with histologically proven low-grade OALs were enrolled in this study. Staging included CT-scan of the orbit, neck, chest and abdomen, MR of the orbit, Chlamydia psittaci (Cp) detected by PCR and bone marrow biopsy. Treatment consisted of chlorambucil (0,1 mg/Kg/die for 45 days, then on days 1 to 15 monthly for 4 months) and rituximab (375 mg/sqm weekly for 4 doses, then monthly for 4 infusions). Toxicities were reported according to WHO criteria. At the end of treatment patients were restaged clinically and with a MR of the orbit. Results: Since November 2003 to November 2010 twenty consecutive, histologically proven, low-grade OALs (19 EMZL, a grade I follicular lymphoma) have been treated according to protocol. The median interval between onset of the first symptoms and diagnosis was 13 months (range, 4 months – 3 years). Twelve pts were female (60%) and eight pts were male (40%). Median age at diagnosis was 68 years (range, 35–86 years). Disease was localized in the conjunctiva in 15 patients (75%), in the lacrimal glands in 2 patients (10%) and in other orbital sites in the last three patients (15%). Nineteen patients presented a stage I disease, one stage IV, and no patient showed B-symptoms. LDH was within normal range in 17 of 20 patients (85%), ECOG-PS was 0 and International prognostic Index (IPI) was low or low-intermediate in all patients. We evaluated PCR for Chlamydia psittaci in the first ten consecutive pts and it was negative. All patients completed the treatment without delay; there was no grade III-IV toxicities neither hospitalizations. Five patients had grade 1–2 rituximab infusion-related reactions usually during the first infusion and haematological toxicity was mild. At the end of treatment 19 patients (95%) resulted in CR, and one obtained a partial remission (5%). After a median follow-up of 56 months (range, 21–106 months) all patients are alive, 17 maintained CR and two relapsed (after 3 and 5 years), one was retreated with the same protocol and attained a new CR and the other relapsed systemically as follicular lymphoma. The patient in PR after first line obtained CR with second line therapy (rituximab fludarabine and cyclophosphamide). The median PFS was 43 months (range, 3–98 months). All patients performed ophthalmologic follow-up visits: we did not report ocular toxicities, and all patients conserved a normal visual function, including acuity. No secondary myelodisplatic syndrome or secondary neoplasms are reported. Conclusions: After a long follow-up the combination of rituximab and chlorambucil proved to be low toxic, feasible and effective therapy for primary OALs. No delayed ocular or haematological complications are reported. For this reason the combination of immunotherapy and mild chemotherapy should be considered for the treatment of this indolent lymphoma. Disclosures: No relevant conflicts of interest to declare.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V120.21.3685.3685

Language: English

Publisher: American Society of Hematology

Publication Date: 2012

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 32-33

Abstract: Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with specific morphologic and molecular features and excellent prognosis. Although high rate of complete response (CR) has been reported after treatment with purine analogs, expecially cladribine (2CDA), relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long term remission rate and overall survival (OS) in those patients (pts) that received 2CDA as first line treatment. We retrospectively reviewed data of all HCL pts treated with 2CDA between March 1991 and May 2019 at 18 Italian Hematological centers. Among 553 pts reported, only 513 were evaluable because treated with 2CDA alone. Considering the clinical carachteristics, M/F ratio was 4.5 with a median age of 54 years (range 24-88) and ECOG 0 in 85% of cases. Splenomegaly and presence of circulating hairy cells recorded by morphology were reported in 241 (47%) and 138 (27%) pts, respectively. Thirty-seven (7%) pts presented with an infection. Other comorbidities were cardiovascular in 29 (6%) pts, a previous cancer or diabetes in 27 (5%) each, chronic hepatic disorders in 18 (3%), obstructive pulmonary disease in 16 (3%), chronic kidney disease in 3 (1%). Three hundred-thirty (64%) pts received 2CDA intravenously (253 as daily continuous infusion for 5-7 consecutive days and 77 as weekly infusion for 5-7 consecutive weeks) and 183 (36%) subcutaneously. Response criteria were defined as per recent consensus guidelines (Grever MR et al. Blood 2017). The overall response rate (ORR) was 83%: CR in 335 pts (65%) and partial response (PR) in 96 (19%); 40 (8%) pts obtained hematological improvement (HI) and in 42 (8%) no response was observed. Nine of 11 (82%) pts with HI and 18/25 (72%) non responders who received salvage therapy obtained a major response (fig. 1). A slightly higher hemoglobin value (12.4 vs 11.4 g/dl, p=0.044), a reduced frequency of circulating hairy cells (28.7% vs 31.8%, p=0.039), absence of palpable splenomegaly (p= & lt;0.001) and a faster recovery of ANC (28 days vs 41 days, p= 0.006) were associated with CR compared to PR in univariable analysis. No differences in terms of quality and duration of response, infection rate and time to blood counts recovery were reported according to the 2 routes of administration. Among pts receiving intravenous 2CDA, ORR was 85% for continuous infusion and 78% for weekly infusion: no statistically significant difference could be observed. Median duration of response was 12.2 years: 75.1%, 53.6% and 45.5% of responding pts are expected to be free from relapse at 5, 10 and 15 years, respectively. A statistically significant difference in duration of response was identified between pts that obtained a CR compared to pts in PR (19.4 years versus 4.7 years, p & lt;0.0001) (fig. 2). No other differences in relapse free survival (RFS) were identified. Non-hematological grade-3 or higher early toxicity was reported in 108 (21%) pts, due to infections in 102 cases (20%), mainly fever of unknown origin and pneumonia. In 6 cases infection due to invasive aspergillosis, bacteric pneumonia and bacteric sepsis caused the death of pts. Other non-hematological adverse events were almost all grade-1 allergy (47 pts, 9%). No late toxicity was reported, but 19 (4%) second cancers were observed. Among 118 pts relapsed after a median of 4.4 years (fig. 1), 85 (72%) were retreated with 2CDA, alone (65 cases) or associated with rituximab (20 cases); 11 (9%) with pentostatin, alone (7 cases) or associated with rituximab (4 cases), 8 (7%) with interferon α, 8 (7%) with rituximab alone, 1 (1%) with vemurafenib and zanubrutinib each; 2 were lost at follow-up and 2 died before retreatment. Overall, 58 (51%) retreated pts obtained a CR (42 after 2CDA), 37 (32%) a PR (32 after 2CDA), 7 (6%) a HI (4 after 2CDA) and 12 (11%) did not show any response (6 after 2CDA). Median OS was not reached; 95.7%, 92.8% and 82.3% of pts are expected to be alive at 5, 10 and 15 years, respectively (fig. 2). Overall 51 pts died (10%), during the induction phase in 6 cases and during follow-up in 45: overall, mortality was HCL-related in 14 patients (2 progression of disease and 12 infections) and HCL-unrelated in 37 patients (cardiovascular events in 16, natural causes in 15, a second cancer in 6). 2CDA is greatly effective in treating HCL, with an ORR of 83%. Early and long term adverse events were rare and easily managed: although HCL-related mortality is still possible, OS at 15 years is higher than 80% Disclosures Motta: Roche: Honoraria; Janssen: Honoraria. Offidani:Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Tedeschi:Abbvie: Honoraria, Speakers Bureau; Sunesis: Honoraria, Speakers Bureau; Acerta: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Beigene: Honoraria, Speakers Bureau. Trentin:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Octapharma: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Shire: Honoraria. Varettoni:Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Other: Travel/accommodations/expenses; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel/accommodations/expenses. Visentin:Janssen: Honoraria; Gilead: Honoraria; Abbvie: Honoraria. Falini:Roche: Research Funding. Pulsoni:Sandoz: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; Gilead: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; roche: Consultancy, Speakers Bureau; Merk: Consultancy. Tiacci:Roche: Research Funding; Abbvie: Other: Travel and meeting expenses. Zinzani:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Portola: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Servier: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kirin Kyowa: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen-Cilag: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Verastem: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Immune Design: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TG Therapeutics, Inc.: Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celltrion: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eusapharma: Consultancy, Speakers Bureau; Kyowa Kirin: Consultancy, Speakers Bureau; Immune Design: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSA Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2020-136633

Language: English

Publisher: American Society of Hematology

Publication Date: 2020

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 1615-1615

Abstract: Abstract 1615 Background: Diffuse large B cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin's lymphoma. R-CHOP21 (C21) is considered the standard therapy but a large number of studies have tested R-CHOP14 (C14). Aims: The aim of our study was to evaluate retrospectively a cohort of patients (pts) treated with C21 or C14 and to compare the efficacy of the therapy. Methods: All pts with diagnosis of DLBCL or follicular grade IIIb lymphoma, treated with curative intent in 9 Italian Hematological Centers, were accrued. All patients treated with C14 used G-CSF as primary prophilaxis, and only elderly (over 70 years) patients treated with C21 used G-CSF as primary prophilaxis. Results: From january 2002 to june 2011, 950 pts were accrued, 643 pts were treated with C21 and 307 were treated with C14. The median age was 63 (range 19–89). The two cohorts of pts were balanced for all clinical characteristics a part for age ( 〈 60 or 〉 60 years) with more aged pts in C21 arm (p 0.001), bone marrow positivity and more than 3 lymph node stations involved that were higher in C14 arm (p: 0.05 and p: 0.001). After induction therapy 751 pts (79%) obtained a complete remission: 501/643 (78%) after C21 and 250/307 (81%) after C14. The remaining pts obtained partial response in 110 and 48 or no response in 32 and 9 respectively for C21 and C14. After a median period of observation of 38 months 104 pts relapsed (14%), 68 (65%) in the C21 arm and 36 (35%) in the C14 arm. After a median observation period of 3 years, considering the two therapies, C21 vs C14, no differences were reported in OS (Figure 1), PFS (Figure 2) and DFS: 80% vs 84%, 69% vs 71% and 54% vs 56% respectively. In univariate analysis OS was lower in older pts (azard ratio (ar): 2.57), IPI 2 (ar: 2.09), IPI 3 (ar: 4.36), IPI 4–5 (ar: 6.36), bulky disease (ar: 1.70), symptomatic disease (ar: 2.23). In multivariate analysis factors which mantained significantly worst prognosis were older age (ar: 1.35), IPI 2 (ar: 1.95), IPI 3 (ar: 3.76), IPI 4–5 (ar: 5.01) and bulky disease (ar: 1.43). As expected hematological grade III/IV toxicity was more frequent in pts treated with C14. No differences in extra-hematological toxicity were observed. Secondary malignancies were reported: 7 in C21 and 3 in C14. After 3 years of median observation 188 pts are dead: 137 (73%) in C21 and 51 (27%) in C14 (not statistically significant, p:0.08). The large majority of pts are dead for disease progression or relapse. Conclusions: In conclusion our results confirm that C14 do not improve the results of the standard C21 in the whole lymphoma population. Dose dense therapy did not affect OS or PFS also analysing sub group of pts. As expected a higher frequency of neutropenia was observed in C21 arm but did not translate in increasing infection rate. Further prospective randomized studies are needed to verify this preliminary observations. Disclosures: No relevant conflicts of interest to declare.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V120.21.1615.1615

Language: English

Publisher: American Society of Hematology

Publication Date: 2012

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Economic Geology, Society of Economic Geologists, Inc., Vol. 115, No. 6 ( 2020-09-01), p. 1343-1361

Abstract: The deepest terminations of the Mount Rudnaya subvertical massive sulfide offshoots of the Norilsk 1 orebody are composed of exceptionally fine grained sulfides that are believed to be natural quenched sulfide solid solutions. Copper-rich intermediate solid solution (ISS) and Fe-rich monosulfide solid solution (MSS) form an equigranular and lamellar matrix hosting MSS- and ISS-dominant globules. The nonstoichiometric chemical compositions of the solid solutions plot within their high-temperature fields known from experiments. MSS contains 19 to 35 wt % Ni, 0.09 to 0.45 wt % Co, and up to 0.6 wt % Cu and is heterogeneously enriched in Rh (up to 32 ppm), Ir (up to 0.6 ppm), Pt (up to 65 ppm), and Pd (up to 168 ppm). ISS occurs as the lamellar intergrowths of the chalcopyrite (Ccpss) and cubanite (Cubss) solid solutions, which bear up to 4.74 wt % Ni and 0.2 wt % Co and are heterogeneously enriched in Zn, Ag, and In. The assemblage of platinum group minerals (PGMs) is hosted mostly in the ISS and is dominated by Pt-Fe alloys and minerals of the rustenburgite-atokite series, like the set of PGMs at the Norilsk 1 deposit. Similar Pt-Pd-Sn compounds in the laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) spectra of profiles through MSS and ISS are interpreted to be trapped microinclusions. The pentlandite contains up to 0.13 wt % Pt, up to 4.62 wt % Pd, & lt;0.53 wt % Co, and & lt;0.4 wt % Cu according to electron microprobe analysis. LA-ICP-MS data and mapping show that Pd content in the pentlandite increases toward contacts with ISS and decreases toward contacts with MSS, supporting a reaction origin of pentlandite. The wide variations of the concentrations of major and trace elements in the solid solutions, as well as the coexistence of Pd-poor (a few ppm Pd) and Pd-rich (over 4.62 wt % Pd) pentlandite within a single sample, seem to characterize the different generations of the MSS to MSS-ISS globules, antecrysts, and phenocrysts with the distinct histories of enrichment due to exchange with fractionated Cu-platinum group element-rich residue. The directional distribution of Pd of high-temperature primary magmatic origin is preserved due to rapid quenching of the sulfides from ~650°C.

Type of Medium: Online Resource

ISSN: 1554-0774 , 0361-0128

URL: Article

DOI: 10.5382/econgeo.4741

Language: English

Publisher: Society of Economic Geologists, Inc.

Publication Date: 2020

detail.hit.zdb_id: 217703-1

detail.hit.zdb_id: 2091221-3

SSG: 13